Loading...
XSESP8A
Market cap56mUSD
Aug 03, Last price  
0.36SGD
Name

Cordlife Group Ltd

Chart & Performance

D1W1MN
XSES:P8A chart
P/E
25.79
P/S
1.63
EPS
0.01
Div Yield, %
0.00%
Shrs. gr., 5y
0.16%
Rev. gr., 5y
-1.57%
Revenues
56m
+1.04%
25,673,00030,275,00034,702,00049,087,00042,764,94659,627,00059,962,00068,309,00060,331,63445,795,56044,631,33241,997,39555,156,00055,730,000
Net income
4m
-27.91%
8,476,0006,926,00013,484,00030,521,00024,106,94312,329,000-2,572,0003,272,0001,776,6754,812,4044,953,6564,546,6484,887,0003,523,000
CFO
10m
+64.80%
8,035,0006,033,0008,665,0003,667,0000-4,010,0001,972,0008,966,00010,209,0009,841,22213,078,3498,891,7175,944,0009,796,000
Earnings
May 13, 2025

Profile

Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. The company operates through two segments, Banking and Diagnostics. It provides cord blood, cord lining, and cord tissue banking services comprising processing and storage of stem cells; and non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening, and newborn genetic screening services. The company also offers preimplantation genetic screening, endometrial receptivity test, paediatric allergen test, and genetic talent test services, as well as moms up, a mobile app for pregnancy and parenting resources. In addition, it provides management, marketing, and property investment services. Cordlife Group Limited was incorporated in 2001 and is headquartered in Singapore.
URL
http://www.cordlife.com/sg/en/
IPO date
Mar 29, 2012
Employees
Domiciled in
SG
Incorporated in
SG

Valuation

Title
SGD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122018‑062017‑062016‑062015‑06
Income
Revenues
55,730
1.04%
55,156
31.33%
41,997
-5.90%
Cost of revenue
56,725
54,259
49,421
Unusual Expense (Income)
NOPBT
(995)
897
(7,424)
NOPBT Margin
1.63%
Operating Taxes
692
617
648
Tax Rate
68.78%
NOPAT
(1,687)
280
(8,072)
Net income
3,523
-27.91%
4,887
7.49%
4,547
-8.22%
Dividends
(2,304)
(2,298)
Dividend yield
2.24%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
(5,537)
1,199
1,574
Long-term debt
5,197
3,235
1,468
Deferred revenue
67,280
49,734
Other long-term liabilities
66,787
522
272
Net debt
(29,652)
(116,234)
(101,035)
Cash flow
Cash from operating activities
9,796
5,944
8,892
CAPEX
(2,273)
(2,396)
(1,164)
Cash from investing activities
(2,631)
4,431
Cash from financing activities
(1,860)
(11,675)
FCF
(13,919)
2,103
(11,688)
Balance
Cash
65,009
65,170
48,087
Long term investments
(35,697)
55,498
55,989
Excess cash
26,526
117,910
101,977
Stockholders' equity
170,298
228,147
174,385
Invested Capital
179,418
85,738
50,512
ROIC
0.41%
ROCE
0.43%
EV
Common stock shares outstanding
256,294
256,229
256,232
Price
0.40
0.00%
Market cap
102,493
-0.05%
EV
1,651
EBITDA
3,035
4,580
(7,424)
EV/EBITDA
Interest
268
152
148
Interest/NOPBT
16.95%